Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), relating to its proposed merger with Neurogene Inc. Under the terms of the agreement, NLTX shareholders are expected to own approximately 16% of the combined company.
Case Type: Mergers & Acquisitions
Sculptor Capital Management Inc.
Sculptor Capital Management Inc. (NYSE: SCU), relating to its proposed sale to Rithm Capital Corp. Under the terms of the agreement, Class A SCU shareholders are expected to receive $11.15 in cash per share they own.
Pardes Biosciences, Inc
Pardes Biosciences, Inc. (Nasdaq: PRDS), relating to its proposed sale to MediPacific, Inc. Under the terms of the agreement, PRDS shareholders are expected to receive at least $2.02 plus an additional cash amount of at most $0.17 in cash per share they own, as well as one non-tradeable CVR.
Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc. (Nasdaq: SGTX), relating to its proposed sale to Eli Lilly and Co. Under the terms of the agreement, SGTX shareholders are expected to receive $14.92 in cash per share they own plus one contingent value right worth up to $111.64.
Immunome, Inc.
Immunome, Inc. (Nasdaq: IMNM), relating to its proposed merger with Morphimmune.
Great Ajax Corp.
Great Ajax Corp. (NYSE: AJX), relating to its proposed sale to Ellington Financial Inc. Under the terms of the agreement, AJX shareholders are expected to receive 0.5308 shares of Ellington per share they own.
American Equity Investment Life Holding Co.
American Equity Investment Life Holding Co. (NYSE: AEL), relating to its proposed sale to Brookfield Reinsurance. Under the terms of the agreement, AEL shareholders are expected to receive 0.49707 shares of Brookfield and $38.85 in cash per share they own.
Western Asset Mortgage Capital Corp.
Western Asset Mortgage Capital Corp. (NYSE: WMC), relating to its proposed merger with Terra Property Trust, Inc.
Eneti, Inc.
Eneti, Inc. (NYSE: NETI), relating to its proposed sale to Cadeler A/S. Under the terms of the agreement, NETI shareholders are expected to receive 3.409 shares of Cadeler per share they own.
Conformis, Inc.
Conformis, Inc. (Nasdaq: CFMS), relating to its proposed sale to restor3d. Under the terms of the agreement, CFMS shareholders are expected to receive $2.27 in cash per share they own.